Cleared Traditional

K233326 - Merge Hemo, Model RCSV2 (FDA 510(k) Clearance)

Jun 2024
Decision
266d
Days
Class 2
Risk

K233326 is an FDA 510(k) clearance for the Merge Hemo, Model RCSV2. This device is classified as a Computer, Diagnostic, Programmable (Class II - Special Controls, product code DQK).

Submitted by Merge Healthcare Incorporated (Hartland, US). The FDA issued a Cleared decision on June 21, 2024, 266 days after receiving the submission on September 29, 2023.

This device falls under the Cardiovascular FDA review panel. Regulated under 21 CFR 870.1425.

Submission Details

510(k) Number K233326 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 29, 2023
Decision Date June 21, 2024
Days to Decision 266 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF

Device Classification

Product Code DQK — Computer, Diagnostic, Programmable
Device Class Class II - Special Controls
CFR Regulation 21 CFR 870.1425

Similar Devices — DQK Computer, Diagnostic, Programmable

All 45
HemoSphere Nano Monitor (HSNANO1)
K253186 · Edwards Lifesciences, LLC · Feb 2026
CARTO™ 3 EP Navigation System V8.4
K252972 · Biosense Webster, Inc. · Feb 2026
Holter ECG and ABP system (HolterABP)
K251591 · Edan Instruments, Inc. · Feb 2026
CARTO™ 3 EP Navigation System V9.0 with PIU Plus
K254085 · Biosense Webster, Inc. · Jan 2026
LumiGuide Equipment R2.1
K252645 · Philips Medical Systems Nederland B.V. · Oct 2025
EnSite™ X EP System
K252013 · Abbott Medical · Sep 2025